What semaglutide tablets are used for — and how the oral form works

Step 1: Understand which tablet does what

There is a persistent misunderstanding worth clearing up gently: not every semaglutide tablet is the same medicine for the same purpose. Rybelsus (the original oral semaglutide) is licensed solely for type 2 diabetes at doses of 3mg, 7mg and 14mg. Wegovy tablets are an entirely separate product, approved at much higher doses (1.5mg up to 25mg), specifically for weight management in adults. The two products share an active ingredient but differ in their licensed uses, their dose strengths, and the clinical criteria for prescribing them. Searching for "semaglutide tablets" and landing on information about one when you need the other is a genuinely common source of confusion, and our guide to semaglutide tablets use explains those differences in practical terms. You can read a detailed breakdown of how the weight-loss tablet works on our semaglutide tablets overview page.

For weight management, the licensed indication covers adults with a BMI of 30 or above, or a BMI of 27 to 29.9 alongside at least one weight-related condition such as high blood pressure, high cholesterol, or obstructive sleep apnoea. A prescriber reviews the full clinical picture before any prescription is written.

Step 2: The dose schedule and how the tablet is taken

Wegovy tablets start at 1.5mg once daily. The prescriber then titrates through 4mg and 9mg before reaching the 25mg maintenance dose, spending at least one month at each level. This graduated approach exists to give the body time to adjust, gastrointestinal side effects such as nausea are most common in the early weeks and generally ease with time.

The absorption mechanism sets oral semaglutide apart from the injection. The tablet uses a compound called SNAC to carry semaglutide through the stomach lining, but that process is easily disrupted. The tablet must be taken first thing in the morning on a completely empty stomach, swallowed whole with no more than about 120ml of plain water, and the 30-minute wait before any food, coffee, or other oral medicine is non-negotiable, not a guideline but a pharmacological requirement. Get that routine right and the tablet performs as intended. The 25mg maintenance tablet page covers the top dose in more detail.

One practical advantage over the injection: no refrigeration. The tablets store at room temperature, which makes travel straightforward.

Step 3: What the evidence says about weight-loss use

The phase 3 trial underpinning the MHRA's approval for weight management was OASIS 4, which ran for 64 weeks and enrolled 307 adults with obesity or overweight plus at least one weight-related condition, none of whom had type 2 diabetes. Participants took 25mg oral semaglutide or placebo alongside lifestyle guidance. Average weight loss in the semaglutide group was around 13.6%, compared with roughly 2.4% in the placebo group. Among participants who adhered fully to treatment throughout, the figure rose to approximately 17%, though that higher number should always be read in context rather than treated as a typical outcome. The trial findings, together with the MHRA approval timeline, are detailed in the MHRA's approval announcements on GOV.UK.

Beyond weight management, the MHRA conditionally approved semaglutide (Wegovy injection) in July 2026 for MASH (a form of fatty liver disease involving moderate-to-advanced fibrosis) in adults. That approval is for the injection, not the tablet, and is separate from the weight-management indication. For completeness on the injection's uses, the oral versus injection comparison covers both formats side by side.

Step 4: Safety considerations specific to oral use

The side-effect profile of oral semaglutide is broadly similar to the injection, nausea, loose stools, constipation, indigestion and burping are the most commonly reported effects, typically peaking in the early dose-escalation phase and settling over weeks. In the OASIS 4 trial, 74% of participants on oral semaglutide reported a gastrointestinal side effect at some point versus 42% on placebo; most were mild to moderate and transient. The NHS semaglutide medicines page covers the full side-effect profile with NHS-verified guidance on when to seek help.

Wegovy tablets are not recommended during pregnancy, breastfeeding, or when trying to conceive. They are not licensed for people under 18. Anyone with a history of certain gastrointestinal conditions, pancreatitis, or medullary thyroid carcinoma should discuss this with a prescriber before starting. Because the tablet is swallowed and absorbed differently from the injection, the interaction with oral contraceptives (absorbed through the gut) is worth raising with a prescriber, particularly for anyone who takes the pill as their primary contraception. The general FAQs address a number of common questions about drug interactions.

Oral semaglutide is not currently available on the NHS; NICE would need to complete a technology appraisal first. For now it is a private prescription only, and the Wegovy tablet cost page gives an honest overview of what private treatment typically involves. If you would like a prescriber to review whether oral semaglutide suits your situation, speaking to our prescribers is the natural next step.